Kane Biotech Retains Edison Advisors as Investor Relations Counsel
WINNIPEG, Manitoba, Feb. 01, 2018 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (OTCQB:KNBIF), (the “Corporation” or “Kane Biotech”) is pleased to announce that it has retained Edison Advisors (“Edison”), a global strategic advisory firm, as the Corporation’s investor relations counsel.
Edison has been engaged to provide investor relations services to Kane Biotech as it works towards its mission to be a global leader in creating innovative technologies for licensing and product commercialization that breakdown and disperse biofilms.
Mark Ahrens-Townsend, President & CEO of Kane Biotech, said, "We look forward to leveraging Edison’s strategic capabilities in capital markets, shareholder communications, and investor marketing. We strongly believe Edison is the right partner to build a U.S. investor base, composed of both retail and institutional investors."
Peter Molloy, Chief Executive Officer of Edison Group, North America, added, “It’s great to be working with Kane Biotech, a leader in the expanding biofilms industry. One of the key issues that Edison will be addressing is the lack of appreciation of the sheer breadth of applications that biofilm resistance is critical in. Kane Biotech’s commitment to developing technologies and products to meet the demand for safe and effective anti-biofilm compounds for the companion pet and human markets, as well as commercial, institutional and industrial markets is unmatched, and we believe this message will resonate well with U.S. investors.”
Edison is a strategic advisory and investment research company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world-renowned equity research platform and deep multi-sector expertise. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Learn more at www.edisongroup.com.
About Kane Biotech Inc.
Kane Biotech is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms.
The Corporation has a portfolio of biotechnologies, intellectual property (76 patents and patents pending, trade secrets and trademarks) and products developed by the Corporation’s own biofilm research expertise and acquired from leading research institutions. StrixNB™, DispersinB®, Aledex®, bluestem™, AloSera™, coactiv+™ and Kane® are trademarks of Kane Biotech Inc. The Corporation is listed on the TSX Venture Exchange under the symbol "KNE" and on the OTCQB Venture Market under the symbol “KNBIF”.
For more information, please visit www.kanebiotech.com or contact:
President & CEO, Kane Biotech Inc.
+1 (204) 477-7592
+1 (646) 653-7035
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Released February 1, 2018